Back to all studies
⚖️
Phase 3
Weight Loss
in-person
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Sponsored by Kailera
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Who can participate
- • Adults aged 18–99
- • All genders welcome
- • Diagnosed with or experiencing obesity with diabetes
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.